Carotech Teams with Metagenics

EDISON, N.J.—Carotech Inc. entered into an exclusive license agreement with Metagenics Inc. for the commercialization of Tocomin® SupraBio™ to the practitioner distribution channel in North America. Carotech and Metagenics will collaborate to formulate new, unique products with the specialized tocotrienol complex, and to establish the best product introduction strategy. Metagenics will have the exclusive right to market Tocomin SupraBio to health care professionals, with an option to extend this exclusivity.

“This agreement with Metagenics is of great significance to Carotech in that it recognizes the commercial potential of Tocomin SupraBio in the North American health care practitioner market,” said WH Leong, Carotech’s vice president. “Metagenics will be among the first in the market with this patented bio-enhanced tocotrienol system. We definitely look forward to collaborating with Metagenics, a reputable and experienced nutraceutical company and an ideal long-term strategic partner.”

For more information, visit www.carotech.net or Booth #2048 at SupplySide West.